- Home
- WLGS vs DRMA Comparison
WLGS vs DRMA Comparison
Compare WLGS & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLGS
- DRMA
- Stock Information
- Founded
- WLGS 1981
- DRMA 2014
- Country
- WLGS Hong Kong
- DRMA United States
- Employees
- WLGS N/A
- DRMA N/A
- Industry
- WLGS Engineering & Construction
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- WLGS Consumer Discretionary
- DRMA Health Care
- Exchange
- WLGS Nasdaq
- DRMA Nasdaq
- Market Cap
- WLGS 4.7M
- DRMA 4.5M
- IPO Year
- WLGS 2023
- DRMA 2021
- Fundamental
- Price
- WLGS $0.21
- DRMA $0.75
- Analyst Decision
- WLGS
- DRMA Strong Buy
- Analyst Count
- WLGS 0
- DRMA 1
- Target Price
- WLGS N/A
- DRMA $6.00
- AVG Volume (30 Days)
- WLGS 3.3M
- DRMA 4.2M
- Earning Date
- WLGS 05-06-2025
- DRMA 05-14-2025
- Dividend Yield
- WLGS N/A
- DRMA N/A
- EPS Growth
- WLGS N/A
- DRMA N/A
- EPS
- WLGS 0.02
- DRMA N/A
- Revenue
- WLGS $7,272,879.00
- DRMA N/A
- Revenue This Year
- WLGS N/A
- DRMA N/A
- Revenue Next Year
- WLGS N/A
- DRMA N/A
- P/E Ratio
- WLGS $10.64
- DRMA N/A
- Revenue Growth
- WLGS 66.93
- DRMA N/A
- 52 Week Low
- WLGS $0.20
- DRMA $0.69
- 52 Week High
- WLGS $9.66
- DRMA $6.17
- Technical
- Relative Strength Index (RSI)
- WLGS 28.21
- DRMA 34.82
- Support Level
- WLGS $0.16
- DRMA $0.69
- Resistance Level
- WLGS $0.20
- DRMA $0.85
- Average True Range (ATR)
- WLGS 0.03
- DRMA 0.08
- MACD
- WLGS 0.18
- DRMA -0.00
- Stochastic Oscillator
- WLGS 38.11
- DRMA 21.43
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.